Forest Laboratories, Inc. Reports Fiscal Year Third Quarter 2012 Earnings Per ... - MarketWatch (press release)
Posted by admin / Under MilnacipranForest Laboratories, Inc. Reports Fiscal Year Third Quarter 2012 Earnings Per ... MarketWatch (press release) Sales of Savella(R) (milnacipran HCl), a selective serotonin norepinephrine dual reuptake inhibitor (SNRI) for the management of fibromyalgia, were $26.3 million, an increase of 6.9% from last year's third quarter. Teflaro(R) (ceftaroline fosamil), ... |
Published on Wednesday 8th of February 2012 12:47:25 PM
Read more...
Forest Labs EPS beat consensus forecasts - The Pharma Letter
Posted by admin / Under MilnacipranForest Labs EPS beat consensus forecasts The Pharma Letter Turnover of Savella (milnacipran HCl), a selective serotonin norepinephrine dual reuptake inhibitor (SNRI) for the management of fibromyalgia, was $26.3 million, up 6.9%. The broad-spectrum bactericidal cephalosporin antibiotic Teflaro (ceftaroline ... |
Published on Wednesday 8th of February 2012 12:47:25 PM
Read more...
